OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
Clinical trial NCT02654587 · TERMINATED
Trial details
- NCT number
- NCT02654587
- Sponsor
- OSE Immunotherapeutics
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-12
- Primary completion
- 2021-01-15
- Enrollment
- 219
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.